 MINNEAPOLIS, MN ACCESSWIRE June 22, 2020 Celcuity Inc. CELC, a clinical stage biotechnology company translating discoveries of new cancer sub-types into pioneering diagnostics and expanded therapeutic options for cancer patients, announced today that the Company presented results from studies of its first CELsignia Pathway Activity Test for ovarian cancer in an e-poster at the American Association for Cancer Research AACR Annual Meeting. The 2020 AACR Virtual Annual Meeting is being held in place of the 2020 in-person Annual Meeting. The CELsignia test for ovarian cancer identifies a subset of ovarian cancer patient whose tumors have abnormal c-Met signaling coincident with abnormal HER2 signaling. 